Free Trial

Lantheus (LNTH) Stock Price, News & Analysis

-2.17 (-2.62%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
622,780 shs
Average Volume
1.05 million shs
Market Capitalization
$5.59 billion
P/E Ratio
Dividend Yield
Price Target

Lantheus MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
22.9% Upside
$99.17 Price Target
Short Interest
7.14% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.83mentions of Lantheus in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$57.41 M Bought Last Quarter
Proj. Earnings Growth
From $5.96 to $5.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

194th out of 920 stocks

Diagnostic Substances Industry

3rd out of 13 stocks

LNTH stock logo

About Lantheus Stock (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Stock Price History

LNTH Stock News Headlines

Insider Trading is Good News for These Stocks
Insider Trading is Good News for These Stocks (LNTH)
Lantheus Holdings: Powerful First Quarter
Truist Financial Keeps Their Buy Rating on Lantheus (LNTH)
Evaluating Lantheus Holdings: Insights From 5 Financial Analysts
Lantheus Holdings: Q1 Earnings Snapshot
LNTH Oct 2024 70.000 call
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$326.66 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.30 billion
Cash Flow
$6.83 per share
Book Value
$11.91 per share


Free Float
Market Cap
$5.59 billion
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

LNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price target for 2024?

7 Wall Street analysts have issued 12 month target prices for Lantheus' stock. Their LNTH share price targets range from $96.00 to $100.00. On average, they expect the company's share price to reach $99.17 in the next year. This suggests a possible upside of 22.9% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2024?

Lantheus' stock was trading at $62.00 at the beginning of the year. Since then, LNTH stock has increased by 30.2% and is now trading at $80.70.
View the best growth stocks for 2024 here

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our LNTH earnings forecast

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The medical equipment provider had revenue of $354 million for the quarter, compared to analysts' expectations of $350.44 million. Lantheus had a trailing twelve-month return on equity of 54.10% and a net margin of 33.72%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of 1.810-1.860 for the period, compared to the consensus earnings per share estimate of 1.660. The company issued revenue guidance of $380.0 million-$390.0 million, compared to the consensus revenue estimate of $356.1 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.62%), Janus Henderson Group PLC (5.54%), Westfield Capital Management Co. LP (2.82%), Reinhart Partners LLC. (2.14%), Price T Rowe Associates Inc. MD (2.00%) and Hood River Capital Management LLC (1.62%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Lantheus Alpha Therapy, Llc, Mary Anne Heino, Minnie Baylor-Henry, Paul Blanchfield and Robert J Jr Marshall.
View institutional ownership trends

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LNTH) was last updated on 5/22/2024 by Staff

From Our Partners